Kyowa Kirin

News

Lilly, Regeneron among firms chosen for FDA fast plant pilot

Eli Lilly, Regeneron, and five other drugmakers will take part in an FDA pilot designed to make it quicker and easier to set up manufacturing plants.

News

Cancer risk scuppers Kyowa Kirin's autoimmune disease drug

Kyowa Kirin has terminated all clinical trials of its anti-OX40L antibody rocatinlimab, after cases of cancer were seen in patients taking the drug.

News

Kura Oncology and Kyowa Kirin logos with Komzifti pill bottle

Kura scores FDA okay for rival to Syndax's leukaemia drug

Kura has claimed FDA approval for oral menin inhibitor Komzifti for acute myeloid leukaemia, setting up a battle with Syndax's rival Revuforj.

Patients

How pharma is tackling new direct-to-patient programmes

At Reuters Pharma USA, executives from AstraZeneca, Gilead, Kyowa Kirin, and EVERSANA discussed the what, why, and how of direct-to-patient models.

News

Spain agrees to reimburse Orchard's gene therapy Libmeldy

Spain has agreed to reimburse Orchard Therapeutics' ex vivo gene therapy for the rare childhood disease metachromatic leukodystrophy.

News

Orchard will help Kyowa Kirin grow in gene therapy

Japan’s Kyowa Kirin has reached an agreement to buy Orchard Therapeutics of the UK in a deal valued at up to $478 million, ahead of an FDA decision on the biotech’s lead g

Lilly, Regeneron among firms chosen for FDA fast plant pilot

Cancer risk scuppers Kyowa Kirin's autoimmune disease drug

Kura scores FDA okay for rival to Syndax's leukaemia drug

How pharma is tackling new direct-to-patient programmes

Spain agrees to reimburse Orchard's gene therapy Libmeldy

Orchard will help Kyowa Kirin grow in gene therapy

Lundbeck preps for key bexicaserin data around year-end

Discover a new era of healthcare panel engagement: Grounded ...

Kyowa Kirin

Editor's Picks